{"id":23086,"date":"2026-10-19T15:40:28","date_gmt":"2026-10-19T12:40:28","guid":{"rendered":"https:\/\/farmacija-mic.lv\/?p=23086"},"modified":"2026-10-19T15:47:30","modified_gmt":"2026-10-19T12:47:30","slug":"jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati","status":"publish","type":"post","link":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/","title":{"rendered":"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti"},"content":{"rendered":"\n<p class=\"has-m-font-size wp-block-paragraph\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-ink-2-color\">Hiperlipid\u0113mija ir lip\u012bdu \u2013 holester\u012bna vai triglicer\u012bdu \u2013 l\u012bme\u0146a paaugstin\u0101\u0161an\u0101s plazm\u0101 vai augsta bl\u012bvuma lipoprote\u012bnu (ABLH) l\u012bme\u0146a samazin\u0101\u0161an\u0101s plazm\u0101, kas savuk\u0101rt veicina aterosklerozes att\u012bst\u012bbu un sekojo\u0161i citus nopietnous vesel\u012bbas st\u0101vok\u013cus, k\u0101 sirdsl\u0113kme, insults un perif\u0113ro art\u0113riju slim\u012bba (1). C\u0113lo\u0146i var b\u016bt prim\u0101ri jeb \u0123en\u0113tiski (kas veido ap 20% gad\u012bjumu) vai sekund\u0101ri \u2013 piem\u0113ram, uzturs, noteiktas hroniskas slim\u012bbas vai medikamentu lieto\u0161ana (2).<\/mark><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"has-l-font-size wp-block-paragraph\"><strong>DABISKAIS stat\u012bns Monakol\u012bns K<\/strong><br>Sarkanajos rauga r\u012bsos galven\u0101 akt\u012bv\u0101 viela monakol\u012bns K ir identisks sint\u0113tiskajam stat\u012bnam lovastat\u012bnam p\u0113c \u0137\u012bmisk\u0101s strukt\u016bras un p\u0113c darb\u012bbas meh\u0101nisma (inhib\u0113 HMG-CoA redukt\u0101zi).\u00a0 Austrumos sarkanie r\u012bsi ir biju\u0161i popul\u0101rs l\u012bdzeklis jau daudzus gadsimtus, bet tikai pirms neilga laika tika aprakst\u012bta un p\u0113t\u012bta t\u0101 holester\u012bna l\u012bmeni pazemino\u0161a iedarb\u012bba. Vien\u0101 no kl\u012bniskiem p\u0113t\u012bjumiem apstiprin\u0101ja ZBLH holester\u012bna samazin\u0101\u0161anos par aptuveni 20%, kop\u0113jo kardiovaskul\u0101ro notikumu samazin\u0101\u0161anos par 37% un koron\u0101ro n\u0101ves gad\u012bjumu samazin\u0101\u0161anos par 31%. Ar\u012b kop\u0113j\u0101 mirst\u012bba pacientiem bija zem\u0101ka (\u201332%). 3\u2009mg monakol\u012bna K saturo\u0161o prepar\u0101tu kop\u0113j\u0101 iedarb\u012bba uz ZBLH holester\u012bna l\u012bmeni ir l\u012bdzv\u0113rt\u012bga 10 mg lovastat\u012bna devai. Iesp\u0113jams, ka at\u0161\u0137ir\u012bba sl\u0113pjas lab\u0101k\u0101 monakol\u012bna K biopieejam\u012bb\u0101, \u0146emot v\u0113r\u0101 to izcelsmi (raudz\u0113ti sarkanie r\u012bsi) sal\u012bdzin\u0101jum\u0101 ar \u0137\u012bmiski att\u012br\u012bto savienojumu.<br>Monakol\u012bnu K, t\u0101pat k\u0101 lovastat\u012bnu, metaboliz\u0113 citohroma P450 izoenz\u012bms 3A4 (kas ir atbild\u012bgs par aptuveni 50% cilv\u0113kiem lietoto z\u0101\u013cu metabolismu), t\u0101p\u0113c past\u0101v teor\u0113tiska z\u0101\u013cu mijiedarb\u012bbas iesp\u0113ja, neskatoties uz savienojuma mazo devu (5).<\/p>\n\n\n\n<p class=\"has-l-font-size wp-block-paragraph\"><strong>DABISKAIS stat\u012bns Polikosanols<\/strong><br>Polikosanols ir dabiska viela, ko visbie\u017e\u0101k ieg\u016bst no cukurniedr\u0113m un kas tiek pla\u0161i lietota vair\u0101k nek\u0101 40 pasaules valst\u012bs, pateicoties t\u0101s lip\u012bdu l\u012bmeni pazemino\u0161\u0101m \u012bpa\u0161\u012bb\u0101m.<br>Polikosanolam piem\u012bt ar\u012b citi efekti \u2013 anti\u00adtrombotiska darb\u012bba, aterosklerotisku\u00a0pl\u0101tn\u012b\u0161u jeb pangu stabiliz\u0113jo\u0161as un antioksidanta \u012bpa\u0161\u012bbas. Vair\u0101k nek\u0101 80 kl\u012bniskie p\u0113t\u012bjumi liecina, ka polikosanolam piem\u012bt lipoprote\u012bnu l\u012bmeni pazemino\u0161a iedarb\u012bba, kas ir sal\u012bdzin\u0101ma ar stat\u012bniem (6).<br>Lai gan polikosanola darb\u012bbas meh\u0101nisms joproj\u0101m tiek preciz\u0113ts, ir pie\u0146emts, ka t\u0101 lip\u012bdu l\u012bmeni mazino\u0161a iedarb\u012bba tiek sasniegta pateicoties diviem meh\u0101nismiem. Tas modific\u0113 HMG-CoA redukt\u0101zi un t\u0101d\u0113j\u0101di inhib\u0113 holester\u012bna sint\u0113zi (l\u012bdz\u012bgi stat\u012bnu darb\u012bbas meh\u0101nismam); k\u0101 ar\u012b kav\u0113 HMG-CoA redukt\u0101zes sint\u0113zi un\/vai stimul\u0113 t\u0101s no\u0101rd\u012b\u0161anos. Citi dati liecina, ka polikosanols ietekm\u0113 aknu AMP-kin\u0101zes fosforil\u0101ciju, kas, k\u0101 zin\u0101ms, nom\u0101c HMG-CoA aktivit\u0101ti. Turkl\u0101t, polikosanols palielina receptoru medi\u0113tu ZBL uz\u0146em\u0161anu akn\u0101s. Iev\u0113rojami efekti ir nov\u0113roti p\u0113c 6\u20138 \u0101rst\u0113\u0161anas ned\u0113\u013c\u0101m (7). Vien\u0101 no p\u0113t\u012bjumiem 10 mg polikosanola dien\u0101 b\u016btiski samazin\u0101ja kop\u0113jo holester\u012bna l\u012bmeni (par 162%) un zema bl\u012bvuma lipoprote\u012bnu holester\u012bnu (par 21,5%) pacientiem ar II tipa hiperholesterin\u0113miju, sal\u012bdzinot ar placebo\u00a0(8).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"has-l-font-size wp-block-paragraph\"><strong>Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojums dislipid\u0113mijas pacientiem<\/strong><br><\/p>\n\n\n\n<p class=\"has-l-font-size wp-block-paragraph\"><strong>Darba m\u0113r\u0137is<\/strong><br>Noskaidrot, vai dabas vielu terapija ir efekt\u012bva dislipid\u0113mijas pacientiem; noteikt kop\u0113j\u0101 holester\u012bna (KH), zema bl\u012bvuma lipoprote\u012bnu holester\u012bna (ZBLH), augsta bl\u012bvuma lipoprote\u012bnu holester\u012bna (ABLH) un triglicer\u012bdu (TG) l\u012bme\u0146a izmai\u0146as p\u0113c terapijas sa\u0146em\u0161anas.<br><\/p>\n\n\n\n<p class=\"has-l-font-size wp-block-paragraph\"><strong>Materi\u0101li un metodes<\/strong><br>Nov\u0113rojum\u0101 tika iek\u013cauti 105 pacienti, kuru KH l\u012bmenis bija no 4,05 mmol\/l un kuru ZBLH l\u012bmenis bija no 1,84 mmol\/l. Nov\u0113rojuma dal\u012bbnieki 12 ned\u0113\u013cas lietoja Latvij\u0101 ra\u017eotu uztura bag\u0101tin\u0101t\u0101ju AteroLip\u00ae Complex, uz\u0146emot 1 kapsulu dien\u0101. \u0160\u012b prepar\u0101ta sast\u0101v\u0101 ir 50 mg ferment\u0113ta sarkan\u0101 rauga r\u012bsu pulvera, ar akt\u012bvo vielu monakol\u012bnu K 2,5 mg, polikosanols 10 mg, 200 mg hol\u012bna bitartr\u0101ta, ar akt\u012bvo vielu hol\u012bnu 82,6 mg, 25 mg standartiz\u0113ta ol\u012bvu (Olea europea) lapu ekstrakta, ar akt\u012bvo vielu hidroksitirozolu 5 mg, 16\u00a0mg niac\u012bna un 2,5 \u00b5g vitam\u012bna B\u2081\u2082.<br><\/p>\n\n\n\n<p class=\"has-l-font-size wp-block-paragraph\"><strong>Rezult\u0101ti\u00a0<\/strong><br>Nov\u0113rojum\u0101 piedal\u012bj\u0101s \u0123imenes \u0101rsti no Latvijas un Igaunijas. Latvij\u0101 nov\u0113rojums norisin\u0101j\u0101s 7 pils\u0113t\u0101s (R\u012bg\u0101, Daugavpil\u012b, Liep\u0101j\u0101, R\u0113zekn\u0113, J\u016brmal\u0101, Jelgav\u0101, J\u0113kabpil\u012b) un Igaunij\u0101 6 pils\u0113t\u0101s (Tallin\u0101, Tartu, H\u0101psal\u0101, S\u0101rem\u0101, P\u0113rnav\u0101, Viljand\u0113).\u00a0<br>Nov\u0113rojum\u0101 piedal\u012bj\u0101s 105 pacienti, kuru vid\u0113jais vecums bija 56 gadi (iesaist\u012btie pacienti bija vecum\u0101 no 30 l\u012bdz 85 gadiem), 71% sievie\u0161u un 29 % v\u012brie\u0161u. 105 pacientiem tikai veikti KH, ZBLH un ABLH m\u0113r\u012bjumi, savuk\u0101rt 79 pacientiem tika veikti TG m\u0113\u00adr\u012bjumi.\u00a0\u00a0<br>Vadoties no s\u0101kotn\u0113j\u0101 KH l\u012bme\u0146a, dal\u012bbnieki tika sagrup\u0113t tr\u012bs grup\u0101s (A grupa\u00a0 l\u012bdz 5 mmol\/L, B grupa no 5,01 l\u012bdz 6,20 mmol\/l, C grupa 6,21 un vair\u0101k mmol\/l).\u00a0 Visliel\u0101kais samazin\u0101jums bija C grup\u0101 (6,21 un vair\u0101k mmol\/l), kur\u0101 bija visliel\u0101kais s\u0101kotn\u0113jais vid\u0113jais KH l\u012bme\u0146a r\u0101d\u012bjums 7,05 mmol\/l. P\u0113c 12 ned\u0113\u013cu AteroLip\u00ae complex\u00a0 lieto\u0161anas C grupas vid\u0113jais KH l\u012bmenis samazin\u0101j\u0101s par 17,40% jeb par 1,23 mmol\/l (p&lt;0,001). Vid\u0113jais KH l\u012bmenis vis\u0101m grup\u0101m (105 pacientiem) samazin\u0101j\u0101s par 14,83% jeb 0,97 mmol\/l (p&lt;0,001) (sk. 1. att\u0113lu).<\/p>\n\n\n\n<p class=\"has-l-font-size wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"507\" class=\"wp-image-23088\" style=\"width: 1200px;\" src=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/10\/1stt_ateroL.jpg\" alt=\"1.att\u0113ls.  AteroLip\u00ae complex nov\u0113rojuma rezult\u0101ti \u2013 kop\u0113jais holester\u012bns (KH), mmol\/l\" srcset=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/10\/1stt_ateroL.jpg 1476w, https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/10\/1stt_ateroL-300x127.jpg 300w, https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/10\/1stt_ateroL-1024x433.jpg 1024w, https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/10\/1stt_ateroL-1400x592.jpg 1400w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/><br>ZBLH r\u0101d\u012bjumi tika sadal\u012bti \u010detr\u0101s grup\u0101s, vadoties no pacientu s\u0101kotn\u0113j\u0101 ZBLH l\u012bme\u0146a (A grupa l\u012bdz 3,00 mmol\/l, B grupa 3,01 l\u012bdz 4,00 mmol\/l, C grupa 4,01 l\u012bdz 5,00 mmol\/l, D grupa 5,01 mmol\/l un vair\u0101k). Visliel\u0101kais ZBLH l\u012bme\u0146a samazin\u0101jums tika nov\u0113rots D grup\u0101, kur s\u0101kotn\u0113jais vid\u0113jais ZBLH l\u012bmenis bija 5,53 mmol\/l un p\u0113c 12 ned\u0113\u013c\u0101m tas grup\u0101 vid\u0113ji samazin\u0101j\u0101s par 20,53% jeb 1,14 mmol\/l (p&lt;0,001). Kop\u0113jais vid\u0113jais ZBLH l\u012bmenis vis\u0101m grup\u0101m (105 pacientiem) samazin\u0101j\u0101s par 17,21% jeb 0,79 mmol\/l (p&lt;0,001) (sk. 2. att\u0113lu).<\/p>\n\n\n\n<p class=\"has-l-font-size wp-block-paragraph\"><img loading=\"lazy\" decoding=\"async\" width=\"1200\" height=\"526\" class=\"wp-image-23087\" style=\"width: 1200px;\" src=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/10\/2stt_ateroL.jpg\" alt=\"2.att\u0113ls. AteroLip\u00ae\u00a0complex nov\u0113rojuma rezult\u0101ti \u2013 zema bl\u012bvuma lipoprote\u012bnu holester\u012bns (ZBLH), mmol\/l\" srcset=\"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/10\/2stt_ateroL.jpg 1494w, https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/10\/2stt_ateroL-300x132.jpg 300w, https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/10\/2stt_ateroL-1024x449.jpg 1024w, https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/10\/2stt_ateroL-1400x614.jpg 1400w\" sizes=\"auto, (max-width: 1200px) 100vw, 1200px\" \/><br>ABLH r\u0101d\u012bjumi uzr\u0101d\u012bja pozit\u012bvu tendenci 41% pacientu. Vid\u0113jais ABLH l\u012bmenis paaugstin\u0101j\u0101s par 14% jeb 0,17 mmol\/l (p&lt;0,05). Kop\u0113jais vid\u0113jais TG l\u012bmenis samazin\u0101j\u0101s visiem pacientiem par 20,30% jeb 0,43 mmol\/l (p&lt;0,05).<br><\/p>\n\n\n\n<p class=\"has-l-font-size wp-block-paragraph\"><strong>Secin\u0101jumi\u00a0<\/strong><br>Veiktie nov\u0113rojumi par\u0101da, ka, lietojot dabas vielu produktu AteroLip\u00ae complex pacientiem ar paaugstin\u0101tu KH un ZBHL l\u012bmeni, augst\u0101ki rezult\u0101ti jeb r\u0101d\u012bt\u0101ju samazin\u0101jumi tika sasniegti grup\u0101s, kur\u0101s \u0161ie r\u0101d\u012bt\u0101ji s\u0101kotn\u0113ji biju\u0161i augst\u0101ki. Lietojot Latvij\u0101 ra\u017eoto AteroLip\u00ae complex pa vienai kapsulai dien\u0101, 3\u00a0m\u0113ne\u0161u period\u0101 35% pacientu ZBLH l\u012bmenis samazin\u0101j\u0101s par 1 mmol\/l un 44% pacientu KH samazin\u0101j\u0101s par 1 mmol\/l. L\u012bdz ar to var secin\u0101t, ka AteroLip\u00ae complex akt\u012bvo vielu kombin\u0101cija samazina KH, ZBLH, TG un uzlabo ABLH l\u012bmeni 3 m\u0113ne\u0161u period\u0101.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Par pilnu literat\u016bras sarakstu interes\u0113ties redakcij\u0101<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hiperlipid\u0113mija ir lip\u012bdu \u2013 holester\u012bna vai triglicer\u012bdu \u2013 l\u012bme\u0146a paaugstin\u0101\u0161an\u0101s plazm\u0101 vai augsta bl\u012bvuma lipoprote\u012bnu (ABLH) l\u012bme\u0146a samazin\u0101\u0161an\u0101s plazm\u0101, kas savuk\u0101rt veicina aterosklerozes att\u012bst\u012bbu un sekojo\u0161i citus nopietnous vesel\u012bbas st\u0101vok\u013cus, [&hellip;]<\/p>\n","protected":false},"author":20,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_labiux_rail":0},"categories":[76,191,214],"tags":[3015,3018,3016,3017],"mic_flag":[],"class_list":["post-23086","post","type-post","status-publish","format-standard","hentry","category-jaunakie-raksti","category-reklamraksts","category-spec-vied","tag-aterolip","tag-dislipidemija","tag-monakolins-k","tag-polikosanols"],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.3 - aioseo.com -->\n\t<meta name=\"description\" content=\"Hiperlipid\u0113mija ir lip\u012bdu \u2013 holester\u012bna vai triglicer\u012bdu \u2013 l\u012bme\u0146a paaugstin\u0101\u0161an\u0101s plazm\u0101 vai augsta bl\u012bvuma lipoprote\u012bnu (ABLH) l\u012bme\u0146a samazin\u0101\u0161an\u0101s plazm\u0101, kas savuk\u0101rt veicina aterosklerozes att\u012bst\u012bbu un sekojo\u0161i citus nopietnous vesel\u012bbas st\u0101vok\u013cus, k\u0101 sirdsl\u0113kme, insults un perif\u0113ro art\u0113riju slim\u012bba (1). C\u0113lo\u0146i var b\u016bt prim\u0101ri jeb \u0123en\u0113tiski (kas veido ap 20% gad\u012bjumu) vai sekund\u0101ri \u2013 piem\u0113ram, uzturs, noteiktas\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"ugis@mic.lv\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/\" \/>\n\t\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.3\" \/>\n\t\t<meta property=\"og:locale\" content=\"en_US\" \/>\n\t\t<meta property=\"og:site_name\" content=\"Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta property=\"og:description\" content=\"Hiperlipid\u0113mija ir lip\u012bdu \u2013 holester\u012bna vai triglicer\u012bdu \u2013 l\u012bme\u0146a paaugstin\u0101\u0161an\u0101s plazm\u0101 vai augsta bl\u012bvuma lipoprote\u012bnu (ABLH) l\u012bme\u0146a samazin\u0101\u0161an\u0101s plazm\u0101, kas savuk\u0101rt veicina aterosklerozes att\u012bst\u012bbu un sekojo\u0161i citus nopietnous vesel\u012bbas st\u0101vok\u013cus, k\u0101 sirdsl\u0113kme, insults un perif\u0113ro art\u0113riju slim\u012bba (1). C\u0113lo\u0146i var b\u016bt prim\u0101ri jeb \u0123en\u0113tiski (kas veido ap 20% gad\u012bjumu) vai sekund\u0101ri \u2013 piem\u0113ram, uzturs, noteiktas\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2026-10-19T12:40:28+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2026-10-19T12:47:30+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti - Medikamentu Inform\u0101cijas Centrs\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Hiperlipid\u0113mija ir lip\u012bdu \u2013 holester\u012bna vai triglicer\u012bdu \u2013 l\u012bme\u0146a paaugstin\u0101\u0161an\u0101s plazm\u0101 vai augsta bl\u012bvuma lipoprote\u012bnu (ABLH) l\u012bme\u0146a samazin\u0101\u0161an\u0101s plazm\u0101, kas savuk\u0101rt veicina aterosklerozes att\u012bst\u012bbu un sekojo\u0161i citus nopietnous vesel\u012bbas st\u0101vok\u013cus, k\u0101 sirdsl\u0113kme, insults un perif\u0113ro art\u0113riju slim\u012bba (1). C\u0113lo\u0146i var b\u016bt prim\u0101ri jeb \u0123en\u0113tiski (kas veido ap 20% gad\u012bjumu) vai sekund\u0101ri \u2013 piem\u0113ram, uzturs, noteiktas\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/jaunakie-raksti\\\/#listItem\",\"name\":\"Jaun\\u0101kie raksti\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/jaunakie-raksti\\\/#listItem\",\"position\":2,\"name\":\"Jaun\\u0101kie raksti\",\"item\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/jaunakie-raksti\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\\\/#listItem\",\"name\":\"Jaun\\u0101k\\u0101s tendences hiperlipid\\u0113mijas pacientiem:Latvijas un Igaunijas \\u0123imenes \\u0101rstu nov\\u0113rojuma rezult\\u0101ti\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#listItem\",\"name\":\"Home\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\\\/#listItem\",\"position\":3,\"name\":\"Jaun\\u0101k\\u0101s tendences hiperlipid\\u0113mijas pacientiem:Latvijas un Igaunijas \\u0123imenes \\u0101rstu nov\\u0113rojuma rezult\\u0101ti\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/category\\\/jaunakie-raksti\\\/#listItem\",\"name\":\"Jaun\\u0101kie raksti\"}}]},{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\\\/#newsarticle\",\"name\":\"Jaun\\u0101k\\u0101s tendences hiperlipid\\u0113mijas pacientiem:Latvijas un Igaunijas \\u0123imenes \\u0101rstu nov\\u0113rojuma rezult\\u0101ti - Medikamentu Inform\\u0101cijas Centrs\",\"headline\":\"Jaun\\u0101k\\u0101s tendences hiperlipid\\u0113mijas pacientiem:Latvijas un Igaunijas \\u0123imenes \\u0101rstu nov\\u0113rojuma rezult\\u0101ti\",\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/ugis\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/1stt_ateroL.jpg\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\\\/#articleImage\",\"width\":1476,\"height\":624},\"datePublished\":\"2026-10-19T15:40:28+03:00\",\"dateModified\":\"2026-10-19T15:47:30+03:00\",\"inLanguage\":\"en-US\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\\\/#webpage\"},\"articleSection\":\"Jaun\\u0101kie raksti, Rekl\\u0101mraksts, Speci\\u0101lista viedoklis, Aterolip, dislipid\\u0113mija, Monakol\\u012bns K, Polikosanols\",\"dateline\":\"Published on October 19, 2026.\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/ugis\\\/#author\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/ugis\\\/\",\"name\":\"ugis@mic.lv\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4454d24e3c5508a0c61b16269164ff61a96d6a9ea91d5a7a71b99ad72b41784a?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"ugis@mic.lv\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\\\/#webpage\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\\\/\",\"name\":\"Jaun\\u0101k\\u0101s tendences hiperlipid\\u0113mijas pacientiem:Latvijas un Igaunijas \\u0123imenes \\u0101rstu nov\\u0113rojuma rezult\\u0101ti - Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Hiperlipid\\u0113mija ir lip\\u012bdu \\u2013 holester\\u012bna vai triglicer\\u012bdu \\u2013 l\\u012bme\\u0146a paaugstin\\u0101\\u0161an\\u0101s plazm\\u0101 vai augsta bl\\u012bvuma lipoprote\\u012bnu (ABLH) l\\u012bme\\u0146a samazin\\u0101\\u0161an\\u0101s plazm\\u0101, kas savuk\\u0101rt veicina aterosklerozes att\\u012bst\\u012bbu un sekojo\\u0161i citus nopietnous vesel\\u012bbas st\\u0101vok\\u013cus, k\\u0101 sirdsl\\u0113kme, insults un perif\\u0113ro art\\u0113riju slim\\u012bba (1). C\\u0113lo\\u0146i var b\\u016bt prim\\u0101ri jeb \\u0123en\\u0113tiski (kas veido ap 20% gad\\u012bjumu) vai sekund\\u0101ri \\u2013 piem\\u0113ram, uzturs, noteiktas\",\"inLanguage\":\"en-US\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/ugis\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/author\\\/ugis\\\/#author\"},\"datePublished\":\"2026-10-19T15:40:28+03:00\",\"dateModified\":\"2026-10-19T15:47:30+03:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/\",\"name\":\"Medikamentu Inform\\u0101cijas Centrs\",\"description\":\"Farm\\u0101cijas nozares port\\u0101ls farmaceitiem un \\u0101rstiem. Zi\\u0146as, normat\\u012bvie akti, pas\\u0101kumi un t\\u0101l\\u0101kizgl\\u012bt\\u012bba vienuviet kop\\u0161 2001. gada.\",\"inLanguage\":\"en-US\",\"publisher\":{\"@id\":\"https:\\\/\\\/farmacija-mic.lv\\\/en\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti - Medikamentu Inform\u0101cijas Centrs","description":"Hiperlipid\u0113mija ir lip\u012bdu \u2013 holester\u012bna vai triglicer\u012bdu \u2013 l\u012bme\u0146a paaugstin\u0101\u0161an\u0101s plazm\u0101 vai augsta bl\u012bvuma lipoprote\u012bnu (ABLH) l\u012bme\u0146a samazin\u0101\u0161an\u0101s plazm\u0101, kas savuk\u0101rt veicina aterosklerozes att\u012bst\u012bbu un sekojo\u0161i citus nopietnous vesel\u012bbas st\u0101vok\u013cus, k\u0101 sirdsl\u0113kme, insults un perif\u0113ro art\u0113riju slim\u012bba (1). C\u0113lo\u0146i var b\u016bt prim\u0101ri jeb \u0123en\u0113tiski (kas veido ap 20% gad\u012bjumu) vai sekund\u0101ri \u2013 piem\u0113ram, uzturs, noteiktas","canonical_url":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","position":1,"name":"Home","item":"https:\/\/farmacija-mic.lv\/en\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/#listItem","name":"Jaun\u0101kie raksti"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/#listItem","position":2,"name":"Jaun\u0101kie raksti","item":"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/","nextItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/#listItem","name":"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti"},"previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/#listItem","name":"Home"}},{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/#listItem","position":3,"name":"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti","previousItem":{"@type":"ListItem","@id":"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/#listItem","name":"Jaun\u0101kie raksti"}}]},{"@type":"NewsArticle","@id":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/#newsarticle","name":"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti - Medikamentu Inform\u0101cijas Centrs","headline":"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti","author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/ugis\/#author"},"publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/farmacija-mic.lv\/wp-content\/uploads\/2026\/10\/1stt_ateroL.jpg","@id":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/#articleImage","width":1476,"height":624},"datePublished":"2026-10-19T15:40:28+03:00","dateModified":"2026-10-19T15:47:30+03:00","inLanguage":"en-US","mainEntityOfPage":{"@id":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/#webpage"},"isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/#webpage"},"articleSection":"Jaun\u0101kie raksti, Rekl\u0101mraksts, Speci\u0101lista viedoklis, Aterolip, dislipid\u0113mija, Monakol\u012bns K, Polikosanols","dateline":"Published on October 19, 2026."},{"@type":"Organization","@id":"https:\/\/farmacija-mic.lv\/en\/#organization","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","url":"https:\/\/farmacija-mic.lv\/en\/"},{"@type":"Person","@id":"https:\/\/farmacija-mic.lv\/en\/author\/ugis\/#author","url":"https:\/\/farmacija-mic.lv\/en\/author\/ugis\/","name":"ugis@mic.lv","image":{"@type":"ImageObject","@id":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/4454d24e3c5508a0c61b16269164ff61a96d6a9ea91d5a7a71b99ad72b41784a?s=96&d=mm&r=g","width":96,"height":96,"caption":"ugis@mic.lv"}},{"@type":"WebPage","@id":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/#webpage","url":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/","name":"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti - Medikamentu Inform\u0101cijas Centrs","description":"Hiperlipid\u0113mija ir lip\u012bdu \u2013 holester\u012bna vai triglicer\u012bdu \u2013 l\u012bme\u0146a paaugstin\u0101\u0161an\u0101s plazm\u0101 vai augsta bl\u012bvuma lipoprote\u012bnu (ABLH) l\u012bme\u0146a samazin\u0101\u0161an\u0101s plazm\u0101, kas savuk\u0101rt veicina aterosklerozes att\u012bst\u012bbu un sekojo\u0161i citus nopietnous vesel\u012bbas st\u0101vok\u013cus, k\u0101 sirdsl\u0113kme, insults un perif\u0113ro art\u0113riju slim\u012bba (1). C\u0113lo\u0146i var b\u016bt prim\u0101ri jeb \u0123en\u0113tiski (kas veido ap 20% gad\u012bjumu) vai sekund\u0101ri \u2013 piem\u0113ram, uzturs, noteiktas","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/farmacija-mic.lv\/en\/#website"},"breadcrumb":{"@id":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/#breadcrumblist"},"author":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/ugis\/#author"},"creator":{"@id":"https:\/\/farmacija-mic.lv\/en\/author\/ugis\/#author"},"datePublished":"2026-10-19T15:40:28+03:00","dateModified":"2026-10-19T15:47:30+03:00"},{"@type":"WebSite","@id":"https:\/\/farmacija-mic.lv\/en\/#website","url":"https:\/\/farmacija-mic.lv\/en\/","name":"Medikamentu Inform\u0101cijas Centrs","description":"Farm\u0101cijas nozares port\u0101ls farmaceitiem un \u0101rstiem. Zi\u0146as, normat\u012bvie akti, pas\u0101kumi un t\u0101l\u0101kizgl\u012bt\u012bba vienuviet kop\u0161 2001. gada.","inLanguage":"en-US","publisher":{"@id":"https:\/\/farmacija-mic.lv\/en\/#organization"}}]},"og:locale":"en_US","og:site_name":"Medikamentu Inform\u0101cijas Centrs","og:type":"article","og:title":"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti - Medikamentu Inform\u0101cijas Centrs","og:description":"Hiperlipid\u0113mija ir lip\u012bdu \u2013 holester\u012bna vai triglicer\u012bdu \u2013 l\u012bme\u0146a paaugstin\u0101\u0161an\u0101s plazm\u0101 vai augsta bl\u012bvuma lipoprote\u012bnu (ABLH) l\u012bme\u0146a samazin\u0101\u0161an\u0101s plazm\u0101, kas savuk\u0101rt veicina aterosklerozes att\u012bst\u012bbu un sekojo\u0161i citus nopietnous vesel\u012bbas st\u0101vok\u013cus, k\u0101 sirdsl\u0113kme, insults un perif\u0113ro art\u0113riju slim\u012bba (1). C\u0113lo\u0146i var b\u016bt prim\u0101ri jeb \u0123en\u0113tiski (kas veido ap 20% gad\u012bjumu) vai sekund\u0101ri \u2013 piem\u0113ram, uzturs, noteiktas","og:url":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/","article:published_time":"2026-10-19T12:40:28+00:00","article:modified_time":"2026-10-19T12:47:30+00:00","twitter:card":"summary_large_image","twitter:title":"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti - Medikamentu Inform\u0101cijas Centrs","twitter:description":"Hiperlipid\u0113mija ir lip\u012bdu \u2013 holester\u012bna vai triglicer\u012bdu \u2013 l\u012bme\u0146a paaugstin\u0101\u0161an\u0101s plazm\u0101 vai augsta bl\u012bvuma lipoprote\u012bnu (ABLH) l\u012bme\u0146a samazin\u0101\u0161an\u0101s plazm\u0101, kas savuk\u0101rt veicina aterosklerozes att\u012bst\u012bbu un sekojo\u0161i citus nopietnous vesel\u012bbas st\u0101vok\u013cus, k\u0101 sirdsl\u0113kme, insults un perif\u0113ro art\u0113riju slim\u012bba (1). C\u0113lo\u0146i var b\u016bt prim\u0101ri jeb \u0123en\u0113tiski (kas veido ap 20% gad\u012bjumu) vai sekund\u0101ri \u2013 piem\u0113ram, uzturs, noteiktas"},"aioseo_meta_data":{"post_id":"23086","title":null,"description":null,"keywords":null,"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"focus_keyword":null,"additional_keywords":null,"truseo_locale":null,"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_custom_url":null,"og_image_custom_fields":null,"og_image_url":null,"og_image_width":null,"og_image_height":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":null,"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_image_url":null,"twitter_title":null,"twitter_description":null,"schema_type":"default","schema_type_options":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"NewsArticle","isEnabled":true},"graphs":[]},"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"limit_modified_date":false,"ai":{"faqs":[],"keyPoints":[],"schemas":[],"titles":[],"descriptions":[],"socialPosts":{"email":{"subject":"","preview":"","content":""},"linkedin":[],"twitter":[],"facebook":[],"instagram":[]}},"breadcrumb_settings":null,"seo_analyzer_scan_date":null,"created":"2026-10-19 12:40:30","updated":"2026-10-19 12:47:50"},"aioseo_breadcrumb":"<div class=\"aioseo-breadcrumbs\"><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/en\/\" title=\"Home\">Home<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\t<a href=\"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/\" title=\"Jaun\u0101kie raksti\">Jaun\u0101kie raksti<\/a>\n\t\t<\/span><span class=\"aioseo-breadcrumb-separator\">\u00bb<\/span><span class=\"aioseo-breadcrumb\">\n\t\t\tJaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti\n\t\t<\/span><\/div>","aioseo_breadcrumb_json":[{"label":"Home","link":"https:\/\/farmacija-mic.lv\/en\/"},{"label":"Jaun\u0101kie raksti","link":"https:\/\/farmacija-mic.lv\/category\/jaunakie-raksti\/"},{"label":"Jaun\u0101k\u0101s tendences hiperlipid\u0113mijas pacientiem:Latvijas un Igaunijas \u0123imenes \u0101rstu nov\u0113rojuma rezult\u0101ti","link":"https:\/\/farmacija-mic.lv\/en\/jaunakas-tendences-hiperlipidemijas-pacientiemlatvijas-un-igaunijas-gimenes-arstu-noverojuma-rezultati\/"}],"_links":{"self":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/23086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/users\/20"}],"replies":[{"embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/comments?post=23086"}],"version-history":[{"count":4,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/23086\/revisions"}],"predecessor-version":[{"id":23095,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/posts\/23086\/revisions\/23095"}],"wp:attachment":[{"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/media?parent=23086"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/categories?post=23086"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/tags?post=23086"},{"taxonomy":"mic_flag","embeddable":true,"href":"https:\/\/farmacija-mic.lv\/en\/wp-json\/wp\/v2\/mic_flag?post=23086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}